Sclérose en plaques: au-delà des traitements de première ligne [Multiple sclerosis: beyong first line therapies].

Détails

ID Serval
serval:BIB_74AFB87DCACD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Sclérose en plaques: au-delà des traitements de première ligne [Multiple sclerosis: beyong first line therapies].
Périodique
Revue Médicale Suisse
Auteur(s)
Schluep M., Du Pasquier R.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2012
Volume
8
Numéro
339
Pages
946-949
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; ReviewPublication Status: ppublish
Résumé
We are currently experiencing a key period in the management of patients with relapsing remitting multiple sclerosis. The application of new criteria allows early diagnosis, thus at a stage when the available immune treatments are the most likely to show a good efficacy. The therapeutic offer is expanding but its complexity too. It is thus important, for a given patient, to assess as precisely as possible the degree of severity of his/her disease, in order to give the drug with the optimal risk/benefit ratio.
Mots-clé
Adjuvants, Immunologic/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Choice Behavior, Combined Modality Therapy, Humans, Immunosuppressive Agents/therapeutic use, Immunotherapy, Multiple Sclerosis/drug therapy, Multiple Sclerosis/therapy, Patient Education as Topic, Propylene Glycols/therapeutic use, Sphingosine/analogs & derivatives, Sphingosine/therapeutic use, Therapies, Investigational/methods, Therapies, Investigational/utilization
Pubmed
Création de la notice
23/07/2012 17:39
Dernière modification de la notice
03/03/2018 18:22
Données d'usage